ArticleNPJ vaccines2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
Open access · goldAbstract read
In one paragraph
Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis.Epidemiology and infection · 2023Pooled it
- Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.Scientific reports · 2023Pooled it
- Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patients.Scientific reports · 2026Article
- Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV.Microorganisms · 2026Article
- SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.Antibodies (Basel, Switzerland) · 2026Article
- Modeling of longitudinal immune profiles reveals distinct immunogenic signatures following five COVID-19 vaccinations among people living with HIV.Patterns (New York, N.Y.) · 2026Article
- Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.Journal of translational medicine · 2025Article
- Review
- Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV.AIDS (London, England) · 2025Article
- Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count.Journal of Korean medical science · 2025Article
- Article
- Article
- Vaccination against COVID-19 among healthcare workers as a cocoon strategy for people living with HIV.Journal of virus eradication · 2024Article
- T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.Viruses · 2024Article
- SARS-CoV-2 mRNA Vaccines Induce Greater Complement Activation and Decreased Viremia and Nef Antibodies in Men With HIV-1.The Journal of infectious diseases · 2024Article
- Article
- Progress with COVID vaccine development and implementation.NPJ vaccines · 2024Article
- Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.Journal of medical virology · 2024Article
- Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
43 authors at 7 institutions in 1 country.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada. zbrumme@sfu.ca.ORCID http://orcid.org/0000-0002-8157-1037
Francis MwimanziFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Hope R LapointeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.ORCID http://orcid.org/0000-0002-6847-9156
Peter K CheungFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Yurou SangFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Maggie C DuncanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Fatima YaseenDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
Olga AgafiteiFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Siobhan EnnisFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID http://orcid.org/0000-0002-0105-8269
Kurtis NgFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Simran BasraFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Li Yi LimFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Rebecca KalikaweFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Sarah SpeckmaierBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Nadia Moran-GarciaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Landon YoungDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Hesham AliJohn Ruedy Clinic, St, Paul's Hospital, Vancouver, Canada.
Bruce GanaseAIDS Research Program, St. Paul's Hospital, Vancouver, Canada.
Gisele UmviligihozoFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID http://orcid.org/0000-0001-9841-1040
F Harrison OmondiFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Kieran AtkinsonBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Hanwei SudderuddinBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Junine ToyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Paul SeredaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.ORCID http://orcid.org/0000-0002-6411-8089
Laura BurnsDepartment of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada.
Cecilia T CostiniukDivision of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-4547-714X
Curtis CooperDepartment of Medicine, University of Ottawa, Ottawa, Canada.
Aslam H AnisSchool of Population and Public Health, University of British Columbia, Vancouver, Canada.
Victor LeungDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Daniel HolmesDepartment of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada.
Mari L DeMarcoDepartment of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada.ORCID http://orcid.org/0000-0001-9281-9547
Janet SimonsDepartment of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada.
Malcolm HedgcockSpectrum Health, Vancouver, Canada.ORCID http://orcid.org/0000-0001-7510-2173
Marc G RomneyDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Rolando BarriosBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Silvia GuillemiBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.ORCID http://orcid.org/0000-0003-2722-5288
Ralph PantophletFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID http://orcid.org/0000-0003-0490-4747
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Masahiro NiikuraFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Marianne HarrisBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Mark HullBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID http://orcid.org/0000-0001-6432-1426
Simon Fraser University · CAUniversity of British Columbia · CAAIDS Vancouver · CAProvidence Health Care · CASt. Paul's Hospital · CAMcGill University Health Centre · CAUniversity of Ottawa · CA
Funding
BCCDC Foundation for Public Health (BCCDC Foundation for Population and Public Health) VAC-009Genome British Columbia VAC-009Michael Smith Foundation for Health Research (MSFHR) Scholar AwardMichael Smith Foundation for Health Research (MSFHR) VAC-009U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI134229Wellcome Trust (Wellcome) 107752/Z/15/Z
Abstract
Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD), ACE2 displacement and viral neutralization activities one month following the first and second COVID-19 vaccine doses, and again 3 months following the second dose, in 100 adult PLWH and 152 controls. All PLWH were receiving suppressive antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR 525-935) cells/mm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.